Loqtorzi savings card: as little as $0 a dose with commercial insurance

Loqtorzi is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Loqtorzi is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameLoqtorzi

Authorized generictoripalimab-tpzi

Regular generictoripalimab-tpzi

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Loqtorzi?

The original

–

Brand nameThe maker’s card

Loqtorzi Solutions

Savings card from Coherus BioSciences

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a dose

The card takes up to $30,000 a year off your co-pay.

In the maker’s words

“Eligible patients could pay as little as $0 per dose of LOQTORZI.”

From the maker’s offer on loqtorzi.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Loqtorzi itself, from the same company, sold without the brand name, and usually for less. For now Loqtorzi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Loqtorzi is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Nasopharyngeal cancer (upper throat, behind the nose)

What the FDA label says

LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated:

in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC)
as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy

Source: the FDA label for Loqtorzi (Coherus Oncology, Inc.), July 23, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/loqtorzi/